Xencor Inc. (XNCR)
Summary
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
Xencor (XNCR) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.66 per share a year ago.
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript
Xencor Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 85 | $705.37 | $1,268.01 | $562.64 | 79.77% |
| ML Marc Larkins Johnson & Johnson | 748,062 | $30.01M | $11.16M | -$18.85M | -62.8% |
| BG Bart Gancher Intech Investment Management LLC | 58,767 | $816,820.93 | $871,397.08 | $54,576.15 | 6.68% |
 John H. Burbank III Passport Capital LLC | 1.1M | $20.02M | $16.34M | -$3.68M | -18.37% |
| YA Yinka Akinsola Blue Trust Inc. | 222 | $2,604.06 | $3,287.82 | $683.76 | 26.26% |
Xencor Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| GR Gregory Renza Truist Securities | 877.5 | $13,256.93 | $13,144.96 | -$111.97 | -0.84% |
Xencor Inc. (XNCR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Xencor Inc. ever had a stock split?
Xencor Inc. Profile
| Biotechnology Industry | Healthcare Sector | Bassil I. Dahiyat CEO | NASDAQ (NMS) Exchange | 98401F105 CUSIP |
| US Country | 260 Employees | - Last Dividend | - Last Split | 3 Dec 2013 IPO Date |
Overview
Xencor, Inc. is a clinical stage biopharmaceutical company that specializes in the discovery and development of engineered monoclonal antibody and cytokine therapeutics. The company concentrates its efforts on treating a variety of conditions, with a primary focus on cancer and autoimmune diseases. Xencor's innovative approach involves the use of cutting-edge technology to create modified antibodies and cytokines with enhanced therapeutic properties. Established in 1997, Xencor is based in Monrovia, California, where it continues to push the boundaries of medical biotechnology through its robust research and development initiatives.
Products and Services
- Sotrovimab - A therapeutic monoclonal antibody targeting the SARS-CoV-2 virus, produced by Xencor, indicating the company's involvement in the response to the COVID-19 pandemic.
- Ultomiris - Developed for patients suffering from paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, showcasing Xencor's dedication to rare blood disorders.
- Monjuvi - Targets relapsed or refractory diffuse large B-cell lymphoma, underscoring Xencor's focus on cancer therapeutics.
- Plamotamab - A tumor-targeted antibody currently in Phase I clinical trial for non-Hodgkin lymphoma, illustrating the company's commitment to innovating cancer treatment.
- Vudalimab - A bispecific antibody in Phase II clinical trial aimed at treating metastatic castration-resistant prostate cancer and other solid tumor types, reflecting Xencor's work on hard-to-treat cancers.
- Tidutamab - In Phase II clinical trial for neuroendocrine tumors, indicating a focus on specialized oncology areas.
- XmAb306 - Currently in Phase I clinical trial to treat solid tumors, demonstrating Xencor's broad approach to cancer therapy.
- XmAb104 and XmAb841 - Both in Phase I clinical trial targeting selected solid tumors, illustrating the company's diversified pipeline in oncology.
- XmAb564 - A therapy in Phase I clinical trial for autoimmune diseases, showcasing Xencor's interest in immunological disorders.
- AMG 509 - Aimed at prostate cancer and in Phase I clinical trial, highlighting Xencor's ongoing efforts in combating cancer.
- XmAb819 - For patients with renal cell carcinoma, expanding the company's oncology portfolio.
- VIR-3434, VIR-2482, VIR-7832, BMS-986414 + BMS-986413 - Represent Xencor's involvement in collaborations for the development of treatments for hepatitis B, influenza A, COVID-19, and other conditions, further indicating the company's versatility and collaborative approach in tackling various diseases.
- AIMab7195 - Aims to reduce IgE levels that mediate allergic responses, demonstrating Xencor's contribution to allergy treatment.
- Obexelimab - Targets autoimmune diseases, illustrating the company's focus on immune system disorders.
- Xpro1595 - Being developed for Alzheimer's disease, mild cognitive impairment, and depression, showcasing the company's foray into neurological conditions.
In addition to these products, Xencor has a license agreement with Caris Life Sciences, which broadens its research and development reach into cutting-edge cancer diagnostics and therapeutics, further emphasizing its role in advancing medical science.
